{"disease":{"id":"mucocutaneous-leishmaniasis","name":"mucocutaneous leishmaniasis"},"drugs":{"marketed":[{"drug_id":"miltefosine","indication_name":"American mucocutaneous leishmaniasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Impavido","generic_name":"MILTEFOSINE","company_name":"Knight Theraps","drug_phase":"marketed","molecular_target":"RAC-alpha serine/threonine-protein kinase","drug_class":"Antileishmanial [EPC]","quality_score":65,"revenue":null,"mechanism":"Impavido works by inhibiting the RAC-alpha serine/threonine-protein kinase, which is essential for the survival of Leishmania parasites."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}